QIAGEN N.V.

514 articles about QIAGEN N.V.

• QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlook

  8/8/2023

  QIAGEN announced results for the second quarter and first half of 2023.

• QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT® (avapritinib) in gastrointestinal stromal tumors

  8/7/2023

  QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. Food and Drug Administration (FDA) approval of its therascreen PDGFRA RGQ PCR kit (therascreen PDGFRA kit).

• Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement

  7/26/2023

  Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.

• QIAGEN N.V. to release results for Q2 2023 and hold webcast

  7/24/2023

  QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter 2023.

• QIAGEN expands range of digital PCR kits and services for the biopharma industry

  7/18/2023

  QIAGEN announced the expansion of its digital PCR offering for the development of cell and gene therapies in the biopharma industry.

• FBI approves QIAGEN’s NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)

  6/20/2023

  QIAGEN announced that the U.S. Federal Bureau of Investigation has approved its ForenSeq® MainstAY workflow.

• QIAGEN’s QuantiFERON-TB Gold Plus shows unique clinical value with CD8 technology in new meta-analysis of tuberculosis screening

  6/15/2023

  QIAGEN welcomes the publication of a new, systematic review highlighting the unique value of its proprietary tuberculosis testing technology.

• Danish National Genome Center selects QIAGEN for variant interpretation in oncology genome sequencing

  6/13/2023

  QIAGEN announced that its variant interpretation and reporting software, QIAGEN Clinical Insight Interpret, is being deployed as a part of a national initiative in Denmark to offer sequencing-based solutions for cancer patients.

• QIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased risk

  5/3/2023

  QIAGEN announced that it welcomed the U.S. Preventive Services Task Force reaffirming a previously issued recommendation for latent tuberculosis infection screening by primary care physicians in populations at increased risk.

• QIAGEN exceeds outlook for Q1 2023 with 12% CER sales growth in non-COVID product portfolio

  5/3/2023

  Net sales for Q1 2023 declined 23% to $485 million from Q1 2022, which was marked by very strong COVID-19 sales contributions.

• QIAGEN launches QIAstat-Dx in Japan with respiratory panel for syndromic testing

  4/24/2023

  QIAGEN announced that its QIAstat-Dx syndromic testing solution is expected to be available soon for use in Japan with a SARS-CoV-2 Respiratory Panel that can detect more than 20 pathogens from a single patient sample.

• QIAGEN announces expansion of Supervisory BoardSteve Rusckowski has joined Supervisory Board and will stand for election at Annual General Meeting in June 2023

  4/20/2023

  QIAGEN announced that Steve Rusckowski, an internationally recognized healthcare industry executive and former Chairman, President and CEO of Quest Diagnostics, has joined the Supervisory Board as a new member and will stand for election at the next Annual General Meeting scheduled for June 22, 2023.

• QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023

  4/14/2023

  QIAGEN announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers studying cancer and other diseases to turn cell-free DNA liquid-biopsy samples into libraries ready for next-generation sequencing in less than eight hours.

• QIAGEN receives approval for its net-zero carbon emissions target by Science Based Targets initiative (SBTi)SBTi has validated the QIAGEN targets to reach net-zero greenhouse gas (GHG) emissions

  3/27/2023

  QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its emissions reduction targets have been validated by the Science Based Targets initiative (SBTi) – a global recognition of its ambitions to honor the Paris Agreement’s climate goals.

• QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results

  3/13/2023

  QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission.

• QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug

  3/9/2023

  QIAGEN N.V. announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia.

• QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups

  2/7/2023

  QIAGEN N.V. announced results for the fourth quarter and full-year 2022. Net sales for Q4 2022 declined 14% to $498 million from Q4 2021.

• QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast

  1/17/2023

  QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the fourth quarter and full-year 2022.

• Helix and QIAGEN Form Exclusive Global Partnership to Develop and Commercialize Companion Diagnostics for Hereditary Diseases

  1/5/2023

  Helix, the leading population genomics and viral surveillance company in the nation, announced a global strategic partnership with QIAGEN N.V., the leading global provider of Sample to Insight solutions, to jointly develop companion diagnostics for hereditary diseases.

• QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook

  11/7/2022

  QIAGEN N.V. announced results for the third quarter of 2022 and first nine months of 2022, and increased the outlook for full-year 2022.